Business
Prothena to Report Fourth Quarter and Full Year 2025 Financial Results on February 19, 2026
DUBLIN, February 12, 2026--Prothena announced that it will report its fourth quarter and full year 2025 financial results on Thursday 2/19/26 with a conference call at 4:30pm ET
About this update from Prothena Corporation Plc
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":3612,"height":1160,"url":"https://media.zenfs.com/en/business-wire.com/105bf3f95f727b28fda6e4f18240af9f"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/LX2tfT1lGObCllX7_7GxLQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTMwODtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/105bf3f95f727b28fda6e4f18240af9f","width":960,"height":308},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/UJEDN5KSZWndppBvV7JtiQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD03NzA7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/105bf3f95f727b28fda6e4f18240af9f","width":1200,"height":385}},"lazy":false},{"type":"text","content":"DUBLIN, February 12, 2026--(BUSINESS WIRE)--Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that it will report its fourth quarter and full year 2025 financial results on Thursday, February 19, 2026, after the close of the U.S. financial markets. The announcement will be followed by a live audio conference call at 4:30 PM ET.","length":476,"tagName":"p"},{"type":"text","content":"The conference call will be made available on the Company's website at www.prothena.com under the Investors tab in the Events and Presentations section. Following the live audio webcast, a replay will be available on the Company's website for at least 90 days.","length":268,"tagName":"p"},{"type":"text","content":"To access the call via dial-in, please dial +1 (800) 715-9871 (U.S. and Canada toll free) or +1 (646) 307-1963 (international) five minutes prior to the start time and refer to conference ID number 1706941. A replay of the call will be available until February 26, 2026, via dial-in at +1 (800) 770-2030 (U.S. and Canada toll free) or +1 (609) 800-9909 (international), Conference ID Number 1706941.","length":399,"tagName":"p"},{"type":"text","content":"About Prothena","length":14,"tagName":"p"},{"type":"text","content":"Prothena Corporation plc is a late-stage clinical biotechnology company with expertise in protein dysregulation with the potential to change the course of devastating neurodegenerative and rare peripheral amyloid diseases. Fueled by its deep sci...